NASDAQ : ACXP
Acurx Pharmaceuticals, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.04 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.48M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 5.54M | 6.26M | 8.72M | 8.53M | 7.34M | 10.78M |
| Research & Development | 2.12M | 1.83M | 5.40M | 6.04M | 4.75M | 2.03M |
| Operating Expenses | 7.67M | 8.09M | 14.12M | 14.58M | 12.09M | 12.81M |
| Operating Income | -7.67M | -8.09M | -14.12M | -14.58M | -12.09M | -12.81M |
| Interest & Investment Income | 162.82K | 125.44K | 20.12K | |||
| EBT Excluding Unusual Items | -7.51M | -7.97M | -14.10M | -14.58M | -12.09M | -12.81M |
| Other Unusual Items | 66.50K | |||||
| Pretax Income | -7.51M | -7.97M | -14.10M | -14.58M | -12.09M | -12.75M |
| Net Income | -7.51M | -7.97M | -14.10M | -14.58M | -12.09M | -12.75M |
| Net Income to Common | -7.51M | -7.97M | -14.10M | -14.58M | -12.09M | -12.75M |
| Shares Outstanding (Basic) | 2.70M | 1.50M | 808.17K | 633.58K | 540.82K | 426.79K |
| Shares Outstanding (Diluted) | 2.70M | 1.50M | 808.17K | 633.58K | 540.82K | 426.79K |
| EPS (Basic) | -2.78 | -5.32 | -17.45 | -23.01 | -22.36 | -29.87 |
| EPS (Diluted) | -2.78 | -5.32 | -17.45 | -23.01 | -22.36 | -29.87 |
| EBIT | -7.67M | -8.09M | -14.12M | -14.58M | -12.09M | -12.81M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 10.66M | 7.56M | 3.71M | 7.47M | 9.11M | 12.96M |
| Cash & Short-Term Investments | 10.66M | 7.56M | 3.71M | 7.47M | 9.11M | 12.96M |
| Other Receivables | 95.31K | 48.42K | 51.13K | 129.16K | ||
| Receivables | 95.31K | 48.42K | 51.13K | 129.16K | ||
| Prepaid Expenses | 233.08K | 85.02K | 100.12K | 105.78K | 264.95K | 295.30K |
| Total Current Assets | 10.98M | 7.69M | 3.86M | 7.71M | 9.38M | 13.25M |
| Total Assets | 10.98M | 7.69M | 3.86M | 7.71M | 9.38M | 13.25M |
| Accounts Payable | 3.83K | 6.80K | 4.79K | 3.81K | 29.54K | 63.37K |
| Accrued Expenses | 2.83M | 2.41M | 3.24M | 3.04M | 2.03M | 780.53K |
| Total Current Liabilities | 2.83M | 2.42M | 3.24M | 3.04M | 2.06M | 843.91K |
| Total Liabilities | 2.83M | 2.42M | 3.24M | 3.04M | 2.06M | 843.91K |
| Common Stock | 4.68K | 2.35K | 852.00 | 14.47K | 11.63K | 10.22K |
| Additional Paid-In Capital | 87.37M | 80.55M | 67.94M | 57.87M | 45.94M | 38.95M |
| Retained Earnings | -79.22M | -75.29M | -67.32M | -53.22M | -38.64M | -26.55M |
| Shareholders' Equity | 8.15M | 5.27M | 615.12K | 4.67M | 7.32M | 12.41M |
| Total Liabilities & Equity | 10.98M | 7.69M | 3.86M | 7.71M | 9.38M | 13.25M |
| Net Cash (Debt) | 10.66M | 7.56M | 3.71M | 7.47M | 9.11M | 12.96M |
| Net Cash Per Share | 3.95 | 5.04 | 4.59 | 11.80 | 16.85 | 30.36 |
| Filing Date Shares Outstanding | 5.27M | 2.86M | 1.10M | 787.86K | 581.79K | 511.66K |
| Total Common Shares Outstanding | 4.68M | 2.35M | 851.53K | 723.41K | 581.38K | 510.79K |
| Working Capital | 8.15M | 5.27M | 615.12K | 4.67M | 7.32M | 12.41M |
| Book Value Per Share | 1.74 | 2.24 | 0.72 | 6.45 | 12.58 | 24.30 |
| Tangible Book Value | 8.15M | 5.27M | 615.12K | 4.67M | 7.32M | 12.41M |
| Tangible Book Value Per Share | 1.74 | 2.24 | 0.72 | 6.45 | 12.58 | 24.30 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -7.51M | -7.97M | -14.10M | -14.58M | -12.09M | -12.75M |
| Stock-Based Compensation | 1.32M | 1.57M | 3.44M | 3.77M | 3.30M | 6.07M |
| Other Operating Activities | 1.52M | |||||
| Change in Accounts Payable | 241.22K | -408.78K | 200.40K | 980.75K | 1.22M | 387.98K |
| Change in Other Net Operating Assets | -234.66K | 17.82K | 83.69K | 30.02K | 30.35K | -246.69K |
| Operating Cash Flow | -6.18M | -6.79M | -10.38M | -9.80M | -7.54M | -5.01M |
| Issuance of Common Stock | 10.92M | 10.78M | 6.62M | 8.16M | 3.70M | 14.80M |
| Other Financing Activities | -146.03K | -146.03K | ||||
| Financing Cash Flow | 10.78M | 10.64M | 6.62M | 8.16M | 3.70M | 14.80M |
| Net Cash Flow | 4.59M | 3.85M | -3.77M | -1.64M | -3.85M | 9.78M |
| Levered Free Cash Flow | -3.42M | -4.29M | -5.11M | -4.33M | -3.01M | -208.37K |
| Unlevered Free Cash Flow | -3.42M | -4.29M | -5.11M | -4.33M | -3.01M | -208.37K |
| Change in Working Capital | 6.56K | -390.96K | 284.09K | 1.01M | 1.25M | 141.28K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 5.48M | 5.85M | 13.75M | 52.73M | 46.14M | 44.15M |
| Enterprise Value | -5.18M | -60.00K | 7.99M | 45.68M | 35.53M | 29.69M |
| Last Close Price | 1.04 | 2.49 | 16.28 | 76.60 | 79.60 | 86.43 |
| PB Ratio | 0.60 | 1.11 | 22.35 | 11.30 | 6.31 | 3.56 |
| P/TBV Ratio | 0.67 | 1.11 | 22.35 | 11.30 | 6.31 | 3.56 |
| Net Debt / Equity Ratio | -1.31 | -1.43 | -6.03 | -1.60 | -1.25 | -1.04 |
| Quick Ratio | 3.80 | 3.14 | 1.16 | 2.50 | 4.42 | 15.36 |
| Current Ratio | 3.88 | 3.18 | 1.19 | 2.53 | 4.55 | 15.71 |
| Return on Equity (ROE) | -128.11% | -270.80% | -534.03% | -243.33% | -122.61% | -168.71% |
| Return on Assets (ROA) | -55.92% | -87.59% | -152.62% | -106.65% | -66.79% | -97.21% |
| Return on Capital Employed (ROCE) | -94.10% | -153.60% | -2,296.00% | -312.40% | -165.30% | -103.30% |
| Earnings Yield | -267.60% | -136.25% | -102.56% | -27.64% | -26.21% | -28.88% |
| Buyback Yield / Dilution | -179.62% | -85.46% | -27.56% | -17.15% | -26.72% | -37.88% |